About Kura Oncology (NASDAQ:KURA)
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800
Debt
Debt-to-Equity Ratio0.07%
Current Ratio9.44%
Quick Ratio9.44%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.64 per share
Price / Book5.97
Profitability
EPS (Most Recent Fiscal Year)($1.52)
Net Income$-35,430,000.00
Net MarginsN/A
Return on Equity-53.91%
Return on Assets-44.75%
Miscellaneous
Employees32
Outstanding Shares33,350,000
Kura Oncology (NASDAQ:KURA) Frequently Asked Questions
What is Kura Oncology's stock symbol?
Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
How were Kura Oncology's earnings last quarter?
Kura Oncology (NASDAQ:KURA) posted its earnings results on Monday, March, 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.01. View Kura Oncology's Earnings History.
When is Kura Oncology's next earnings date?
What price target have analysts set for KURA?
6 Wall Street analysts have issued 1-year price targets for Kura Oncology's stock. Their predictions range from $18.00 to $28.00. On average, they expect Kura Oncology's stock price to reach $22.00 in the next twelve months. View Analyst Ratings for Kura Oncology.
What are Wall Street analysts saying about Kura Oncology stock?
Here are some recent quotes from research analysts about Kura Oncology stock:
- 1. Cann analysts commented, "The KO-947 phase I program is on track for an on-time enrollment, with data expected in the second half of this year from the phase I study. Findings presented at AACR today could inform future clinical studies for KO-947, by targeting a subset of head and neck, and esophageal patients, based on a precision medicine model. We conclude that KO-947 continues to be a promising asset, based on preclinical data, but is not anticipated to have revenue impact to Kura Oncology by 2022; therefore, we are not making any adjustments to our estimates or outlook." (4/17/2018)
- 2. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (3/22/2018)
Who are some of Kura Oncology's key competitors?
Some companies that are related to Kura Oncology include TG Therapeutics (TGTX), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX), Athenex (ATNX), Zai Lab (ZLAB), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Biohaven Pharmaceutical (BHVN), Assembly Biosciences (ASMB), Alder BioPharmaceuticals (ALDR), Flexion Therapeutics (FLXN), Inflarx (IFRX), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN) and ARMO BioSciences (ARMO).
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the folowing people:
- Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 49)
- Ms. Annette North, Sr. VP & Gen. Counsel (Age 52)
- Dr. Antonio Gualberto, Chief Medical Officer & Head of Devel. (Age 53)
- Ms. Heidi Henson, CFO & Sec. (Age 52)
- Dr. Yi Liu Ph.D., Chief Scientific Officer (Age 50)
Has Kura Oncology been receiving favorable news coverage?
Media headlines about KURA stock have trended positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kura Oncology earned a news sentiment score of 0.25 on Accern's scale. They also gave news stories about the company an impact score of 44.99 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Kura Oncology?
Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kura Oncology's stock price today?
One share of KURA stock can currently be purchased for approximately $15.77.
How big of a company is Kura Oncology?
Kura Oncology has a market capitalization of $547 million. The company earns $-35,430,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. Kura Oncology employs 32 workers across the globe.
How can I contact Kura Oncology?
Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]
MarketBeat Community Rating for Kura Oncology (KURA)
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kura Oncology (NASDAQ:KURA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Kura Oncology in the last 12 months. Their average twelve-month price target is $22.00, suggesting that the stock has a possible upside of 39.51%. The high price target for KURA is $28.00 and the low price target for KURA is $18.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.00 | $22.60 | $18.30 | $15.75 |
| Price Target Upside: | 39.51% upside | 7.36% upside | 16.19% upside | 126.62% upside |
Kura Oncology (NASDAQ:KURA) Consensus Price Target History
Kura Oncology (NASDAQ:KURA) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Kura Oncology (NASDAQ:KURA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Kura Oncology (NASDAQ KURA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 21.80%
Institutional Ownership Percentage: 58.82%
Kura Oncology (NASDAQ KURA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Kura Oncology (NASDAQ KURA) News Headlines
| Source: |
|
Kura Oncology (NASDAQ:KURA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Kura Oncology (NASDAQ KURA) Stock Chart for Monday, April, 23, 2018
Loading chart…
